lisa rosenbaum second article series three appeared new england journal medicine week continues theme bias complicated following money pens pizza slices interesting note response original article least one blog poster apparently googled dr rosenbaum order point potential conflicts interest probably would relevant look standard international committee medical journal editors disclosure form file nejm provide good example one references week piece financial disclosure case suspicion ad hominem approach evaluating science similar vein one authors previous nejm editorial pointed science stand merit independent disclosures credentials initial part article points fact always seemed pretty obvious me association often used suggest significant meaningful conflicts interest oft quoted statistic physicians relationships industry includes counting drug samples donuts workplace significant relationship one previous employers decided hospital employees participate donut rounds physicians i viewed pseudo egalitarian managed care tactic definition means employees hospital relationship industry article also points physicians request drugs included formulary also likely industry relationships i history two separate pharmacy therapeutics p committees major healthcare system major hospital overriding biases drug cost deals pharmaceutical companies major changes year year basis due price differences cost commonly prescribed drugs often based flawed assumption drugs class equivalent hand exclusive deal could made company might also able combine preferred deal common drug curious situation decisions supposed science based p committee biased managed care industry operating strictly cost basis i decided part ways p committee day presented forms fully disclose finances assure conflicts interest usual hype cherished guardians public trust included i thought second looked around room approximately mds pharmds committee brightest well read staff organization i ran hypothetical mind odds i owned stock xyz pharmaceutical i could convince colleagues good idea put expensive drug formulary based word odds i could overcome predominate bias financial well company employed odds i accomplished first two unattainable goals i would actually see profit xyz stock i also thought drug approvals based solely public relations considerations drugs practically worthless demanded advocates incurable diseases explicit decision want run afoul vocal advocates illnesses would bad public relations press i looked back page disclosure form decided i going play game i going pretend one second i needed vetted organization apparently saw destined sainthood i walked away time i long familiar bias listed rosenbaum article disclosure cme presentation could result mockery discreditation difficult enough present pertinent information audience may want entertained without butt jokes sponsored presenter way look behavior reaction modern day witch hunt mentality i declared witch even beyond i clean person room getting heavy handed conflict interest disclosure public relations gimmick many already figured years ago little insulting rosenbaum also discusses previous study nejm far i tell received press anywhere else study authors designed identical fake clinical trial report abstracts studies varying methodological rigor studies three possible funding disclosures pharmaceutical industry nih none experiment internists involved study less likely read entire report less likely prescribe study medication less likely see experiments rigorously conducted sponsored industry rather nih half likely prescribe medications recommended industry sponsored trial nih sponsored trial authors naturally concerned physicians would skeptical even high quality industry sponsored trials might slow acceptance information clinical practice interesting study done industry year team biotechnology firm amgen examined studies considered 'landmark preclinical studies field oncology goal see reproducible findings could confirmed papers non reproducible research led hundreds secondary articles cases led research exposed patients agents resulted directly original research team bayer healthcare similar review preclinical studies identify potential drug targets concluded work reproducible article referenced general industry rule published results academic settings reproduced industrial lab amgen bayer healthcare studies suggest really underestimate amounts academic bias common criticism leveled big pharma critics benefited taxpayer funded basic science research nih studies suggest plenty problems research independent funding stream less rather likely lead drug discovery addition unique information examine issues bias author lists many also points origin word pharmascolds vilify medical products industry portray academics working traitors sellouts authors describe inadequate public response companies physicians criticized full text reference available online another highly informative article rosenbaum demonstrates analyzing conflict interest easy members press professional critics make gives great example year old woman needs aortic valve replacement considerations might based characteristics biases two different cardiologists assessing situation even complex setting would quick refer woman hospice service experience outlining potential biases situation significant task one physicians would attempt day measured discussion conflict interest might provide better approach skeptical critics suggest inappropriate physician relationship pharmaceutical medical devices industry based face physicians want take conservative path avoid unwarranted criticism stay sunshine database george dawson md dfapa rosenbaum l understanding bias case careful study engl med may doi nejmms pubmed pmid kesselheim robertson ct myers ja rose sl gillet v ross km glynn rj joffe avorn randomized study physicians interpret research funding disclosures engl med sep pubmed pmid begley cg ellis lm drug development raise standards preclinical cancer research nature mar doi pubmed pmid prinz f schlange asadullah k believe much rely published data potential drug targets nat rev drug discov aug doi nrd pubmed pmid shaywitz da stossel tp time fight 'pharmascolds wall street journal april wsj articles sb accessed may